TECH · Insider Trading
Bio-Techne Corp.
Every open-market purchase and sale reported by TECH officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-09-30 | John L Higgins | Director | MIXED | +10,378 | −$403.30K |
| 2026-09-24 | Robert V Baumgartner | Director | MIXED | +10,381 | −$403.31K |
| 2026-08-19 | Amy E. Herr | Director | A | — | — |
| 2026-08-19 | James Hippel | CFO | A | — | — |
| 2026-08-19 | William Geist | PRESIDENT, PROTEIN SCIENCES | A | — | — |
| 2026-08-19 | Shane Bohnen | SVP - General Counsel | A | — | — |
| 2026-08-19 | Steven C. Crouse | President - Diag & Spatial Bi | A | — | — |
| 2026-08-19 | Kim Kelderman | Chief Executive Officer | A | — | — |
| 2026-08-18 | William Geist | PRESIDENT, PROTEIN SCIENCES | MIXED | +4,440 | −$143.06K |
| 2026-08-18 | Amy E. Herr | Director | MIXED | +376 | −$15.42K |
| 2026-08-18 | Shane Bohnen | SVP - General Counsel | MIXED | +3,007 | −$97.23K |
| 2026-08-18 | Kim Kelderman | Chief Executive Officer | MIXED | +10,649 | −$783.44K |
| 2026-08-18 | James Hippel | CFO | MIXED | +5,469 | −$312.04K |
| 2026-08-18 | Steven C. Crouse | President - Diag & Spatial Bi | MIXED | +3,476 | −$140.96K |
| 2026-07-31 | James Hippel | CFO | MIXED | +11,044 | −$720.82K |
| 2026-07-30 | Kim Kelderman | Chief Executive Officer | MIXED | +6,314 | −$401.40K |
| 2026-07-27 | Shane Bohnen | SVP - General Counsel | MIXED | +104 | −$3.36K |
| 2026-06-04 | Steven C. Crouse | President - Diag & Spatial Bi | MIXED | +384 | −$10.75K |
| 2026-05-12 | Amy E. Herr | Director | MIXED | — | −$4.51K |
| 2026-05-07 | Kim Kelderman | Chief Executive Officer | MIXED | +2,741 | −$87.00K |
| 2026-05-07 | Shane Bohnen | SVP - General Counsel | MIXED | +1,345 | −$37 |
| 2026-05-07 | James Hippel | CFO | MIXED | +5,045 | −$277.01K |
| 2026-05-05 | Steven C. Crouse | President - Diag & Spatial Bi | MIXED | +483 | −$17.11K |
| 2026-04-24 | James Hippel | CFO | MIXED | +5,903 | −$3.29M |
| 2026-04-24 | Kim Kelderman | Chief Executive Officer | MIXED | +9,981 | −$79.84K |
| 2026-04-16 | Kim Kelderman | Chief Executive Officer | MIXED | +4,412 | −$1.88M |
| 2026-04-07 | Shane Bohnen | SVP - General Counsel | MIXED | +1,519 | −$39.32K |
| 2026-03-04 | Steven C. Crouse | President - Diag & Spatial Bi | A | — | — |
| 2026-02-19 | Amy E. Herr | Director | Sell | −1,976 | −$116.79K |
| 2026-02-05 | Amy E. Herr | Director | MIXED | +22 | −$1.03K |
| 2026-02-03 | Matthew McManus | President - Diag & Spatial Bio | MIXED | +2,956 | −$106.71K |
| 2025-11-05 | William Geist | PRESIDENT, PROTEIN SCIENCES | MIXED | +5,391 | −$282.82K |
| 2025-11-05 | James Hippel | CFO | MIXED | +12,839 | −$742.39K |
| 2025-11-05 | Kim Kelderman | Chief Executive Officer | F | −2,303 | −$144.10K |
| 2025-11-03 | Robert V Baumgartner | Director | A | +1,640 | — |
| 2025-11-03 | Rupert Vessey | Director | A | +1,640 | — |
| 2025-11-03 | Judith V. Klimovsky | Director | A | +1,640 | — |
| 2025-11-03 | Amy E. Herr | Director | A | +1,640 | — |
| 2025-11-03 | Alpna Seth | Director | A | +1,640 | — |
| 2025-11-03 | John L Higgins | Director | A | +1,640 | — |
| 2025-11-03 | Joseph D Keegan | Director | A | +1,640 | — |
| 2025-11-03 | Julie L Bushman | Director | A | +1,640 | — |
| 2025-08-27 | Robert V Baumgartner | Director | MIXED | — | −$585.66K |
| 2025-08-27 | Roeland Nusse | Director | MIXED | — | −$588.23K |
| 2025-08-19 | William Geist | PRESIDENT, PROTEIN SCIENCES | MIXED | +1,820 | −$43.04K |
| 2025-08-19 | Matthew McManus | President - Diag & Spatial Bio | MIXED | +1,757 | −$47.17K |
| 2025-08-19 | Shane Bohnen | SVP - General Counsel | MIXED | +1,191 | −$28.25K |
| 2025-08-19 | Kim Kelderman | Chief Executive Officer | MIXED | +4,238 | −$230.75K |
| 2025-08-19 | Amy E. Herr | Director | MIXED | +178 | −$5.41K |
| 2025-08-19 | James Hippel | CFO | MIXED | +2,084 | −$103.23K |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| James Hippel | CFO | 170,183 | $12.36M |
| John L Higgins | Director | 82,816 | $6.02M |
| Kim Kelderman | Chief Executive Officer | 82,762 | $6.01M |
| Roeland Nusse | Director | 61,599 | $4.47M |
| Robert V Baumgartner | Director | 56,884 | $4.13M |
| William Geist | PRESIDENT, PROTEIN SCIENCES | 24,943 | $1.81M |
| Joseph D Keegan | Director | 15,411 | $1.12M |
| Alpna Seth | Director | 15,411 | $1.12M |
| Rupert Vessey | Director | 10,987 | $798.10K |
| Shane Bohnen | SVP - General Counsel | 10,360 | $752.55K |
| Steven C. Crouse | President - Diag & Spatial Bi | 10,237 | $743.62K |
| Matthew McManus | President - Diag & Spatial Bio | 9,356 | $679.62K |
| Julie L Bushman | Director | 8,775 | $637.42K |
| Judith V. Klimovsky | Director | 3,782 | $274.72K |
| Amy E. Herr | Director | 3,256 | $236.52K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the TECH quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.